

SEMAGLUTIDE solution for injection (Ozempic® ▼) for Type 2 Diabetes Mellitus

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of SEMAGLUTIDE solution for injection (Ozempic® ▼) for Type 2 Diabetes Mellitus

GREY

Semaglutide (Ozempic® ▼) is a Glucagon-like peptide-1 (GLP-1) mimetic which is licensed for the treatment of adults with insufficiently controlled Type 2 Diabetes Mellitus as an adjunct to diet and exercise:

- > As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
- > In addition to other medicinal products for the treatment of diabetes.¹

It is available as a pre-filled pen in the following strengths; 0.25 mg solution for injection, 0.5 mg solution for injection and 1 mg solution for injection.¹

Semaglutide has been considered as part of the annual round of horizon scanning and has been prioritised for review by the Formulary and Guidelines Subgroup during financial year 2019/20.

In the meantime, clinicians should continue to follow national guidance and prescribe local formulary choices for the treatment of Type 2 Diabetes Mellitus:

- > NICE Guideline [NG28] (May 2017) - [Type 2 diabetes in adults: management](#)
- > Pan Mersey Formulary - [Drugs used in diabetes](#)
- > Pan Mersey prescribing policy statement (September 2016) - [GLP-1 mimetics in combination with insulin](#)

References

1. Novo Nordisk Limited. Summary of Product Characteristics; Ozempic, October 2018. Accessed 15 January 2019 at: <https://www.medicines.org.uk/emc/product/9728/smpc>

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.